Document Type: Research Articles
Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran.
Department of Laboratory Medicine, Department of Experimental Cancer Medicine, Karolinska Institutet Huddinge, 141 86 Stockholm, Sweden.
Molecular Genetics and Microbiology, University of Toronto, Toronto, Ontario, Canada.
Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Objective: Small non-coding RNA molecules are dysregulated in prostate cancer (PCa). In our previous study,
downregulation of miR-1266 and miR-185 was demonstrated in PCa tissues and cell lines. The aim of the present
study was to investigate whether miR-1266 and miR-185 are involved in the regulation of B-cell lymphoma (BCL) 2
and BCL2L1, respectively, and whether transfection of PCa cell lines with miR-1266 and miR-185 mimics can alter
tumorigenic phenotypes. Methods: In order to investigate the regulation of BCL2 and BCL2L1 mRNA levels by
miR-1266 and miR-185, respectively, a luciferase reporter assay was used. Real-time PCR was also used to analyze
changes in the levels of BCL2 and BCL2L1 mRNAs in PCa cell lines following transfection with synthetic miR-1266
and miR-185. Cell apoptosis was determined by Annexin V protein expression analysis via flow cytometry. In addition
to the MTT assay, a cell proliferation assay was performed. Result: A luciferase assay confirmed that the BCL2 and
BCL2L1 genes may be targeted by miR-1266 and miR-185, respectively, through binding to their 3′UTR regions.
Transfection of PC3 and DU145 cells with miR-1266 and miR-185 induced apoptosis and reduced proliferation, which
also revealed an inverse correlation with BCL2 and BCL2L1 gene expression in the treated cells. Conclusion: Our
data suggests that miR-1266 and miR-185 may be novel candidates for further research in PCa treatment through the